Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,357.20
(
0.00%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
106.94
(
-0.50%
)
Bitcoin
77,043.38
(
-0.47%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 82247

Monday, 07/26/2010 7:02:31 PM

Monday, July 26, 2010 7:02:31 PM

Post# of 257580
MNTA—A little knowledge is a dangerous thing: this pseudo-analyst thinks MNTA’s share price went up because it has Hatch-Waxman 180-day marketing exclusivity for generic Lovenox:

http://quicktake.morningstar.com/StockNet/san.aspx?id=345379&SR=COM807

This unexpected conclusion to the race for a generic Lovenox is a boon to Momenta, which has a lucrative profit-sharing arrangement with Novartis that was contingent upon Momenta's securing the 180-day exclusivity period and locking out other competitors.

Someone needs to let this sorry excuse for an analyst know that the H-W 180-day exclusivity period for generic Lovenox expired in Mar 2009.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Where Real Traders Talk Markets

Join thousands of traders sharing insights, catalysts, and charts.

Join Today